2023 World Conference on Lung Cancer (Posters)-EP09.04. Prognostic Factors for Patients With KRAS Mutated Non-Small Cell Lung Cancer and Brain Metastases

EP09.04. Prognostic Factors for Patients With KRAS Mutated Non-Small Cell Lung Cancer and Brain Metastases - PDF(Slides)

Back to course

Pdf Summary

Researchers conducted a study to explore clinical parameters that may affect overall survival in patients with KRAS-mutated non-small cell lung cancer (NSCLC) and brain metastases. The study included 87 patients with brain metastasized KRAS-mutated NSCLC who were treated at Karolinska University Hospital in Stockholm, Sweden between January 2011 and December 2017. <br /><br />The variables that were found to independently influence overall survival in the multivariate analysis were performance status (PS) of 2, where a higher PS was associated with a lower risk of death; having three or more brain metastases, where a lower number of metastases was associated with a lower risk of death; adenocarcinoma histology, where patients with adenocarcinoma had a lower risk of death compared to other histology types; the presence of extracranial disease, where patients with extracranial disease had a higher risk of death; and age, where older age was associated with a higher risk of death.<br /><br />The median overall survival from the time of lung cancer diagnosis was 8.0 months, while the median survival after diagnosis of brain metastasis was 4.0 months. These results indicate that patients with KRAS-mutated NSCLC and brain metastasis have a poor prognosis.<br /><br />The researchers concluded that further analysis is ongoing to develop a KRAS-mut specific prognostic score using the identified variables and co-mutational status. This study contributes to the understanding of the prognostic factors for patients with KRAS-mutated NSCLC and brain metastases, which is important for guiding treatment decisions and improving outcomes for this challenging patient group.

Asset Subtitle

Simon Ekman

Meta Tag

Speaker Simon Ekman

Topic Metastatic NSCLC: Local Therapies - Predictive & Prognostic Biomarkers

Keywords

clinical parameters

overall survival

KRAS-mutated

non-small cell lung cancer

NSCLC

brain metastases

Karolinska University Hospital

performance status

brain metastasis

prognostic factors